Company intelligence / Profile preview

InSCREENeX GmbH

Braunschweig, Lower Saxony, Germanyinscreenex.de ↗

Ownership: Private
Development stage: Commercial

Overview

InSCREENeX does not develop therapeutics directly but provides advanced engineered mammalian cell platforms that accelerate biopharmaceutical R&D. Their technologies are used to generate stable or physiologically relevant cellular models for target validation and compound screening. Recent collaborations include developing a Mammalian Display platform for antibody discovery with YUMAB.

No clinical results as the company does not run clinical trials itself.

Therapeutic areas: Other
Modalities: Engineered mammalian cell systems (for screening and drug development)Stable transgenic cell linesImmortalized primary cells
Industry: Drug Discovery Services

Partnerships

YUMAB GmbHECACCAscenion GmbHTytonis B.V.

Beyond the preview

Go deeper on InSCREENeX GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InSCREENeX GmbH.

Explore the full profile